## **Special Issue**

# Tumor Microenvironment Targeted Nanotherapy

## Message from the Guest Editors

Recent findings suggest that the cellular and extracellular materials surrounding cancerous cells in an atypical tumor microenvironment (TME) play a pivotal role in tumor initiation and progression processes. The TME comprises an intricate system involving diverse cell types, including endothelial cells, pericytes, smooth muscle cells, fibroblasts, various inflammatory cells, dendritic cells, and cancer stem cells (CSCs). TMEforming cells dynamically interact with cancerous cells through various signaling mechanisms and pathways. Present-day researchers thus have a particular interest in exploiting these relationships to develop nanotherapeutics. Nanoparticles' benefits include their ability to passively target through the EPR effect and capacity to be easily be modified with a variety of moieties for active targeting. Moreover, they can utilize the altered tumor environment to promote drug accumulation at tumor sites and modulate the tumor microenvironment by carrying drugs. This Special Issue welcomes both reviews and original articles shedding light on nanotherapeutics targeting or regulating the tumor microenvironment.

## **Guest Editors**

Dr. Chaoyong Liu

College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China

Dr. Haihua Xiao

Key Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China

### Deadline for manuscript submissions

closed (20 April 2023)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/117046

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

